SGLT2 Inhibition Updates 2021 - SGLT2 Inhibition in Cardiorenal Disease
Published: 20 July 2021
Part 1 | Session 2 SGLT2 Inhibitors for Patients with Diabetes and an Increased CV Risk: How The Success Story Started Bernard Zinman
Part 1 | Session 3 SGLT2 Inhibitors: Evolution from Glucose Lowering to Cardiorenal Protection Milton Packer
Part 1 | Session 6 Panel Discussion Stefan Anker, Shelley Zieroth, Andrew JS Coats, Bernard Zinman, John JV McMurray, Katherine Tuttle
Part 2 | Session 1 Place of SGLT2 Inhibitors in the Heart Failure Treatment Algorithm Andrew JS Coats
Part 2 | Session 4 Panel Discussion Andrew JS Coats, Gerasimos Filippatos, Shelley Zieroth, Stefan Anker
Part 7 | Session 2 Keynote Lecture - SGLT2 Inhibitors for Heart Failure: The New Standard of Care Milton Packer
Organised with scientific co-chairs Stefan Anker and Andrew Coats, this event includes presentations and panel discussions with a host of international thought-leaders.
The SGLT2 Updates 2021 conference SGLT2 Inhibition in Cardiorenal Disease: Translating Evidence into Clinical Practice covers the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.
In addition to plenary sessions and satellite symposia the conference featured a number of Meet The Expert breakout sessions discussing the implications in treatment of specific patient subgroups including patients with comorbidities. Audience questions were submitted throughout and were addressed by the panel experts.
SGLT2 Inhibition in Cardiorenal Disease
- Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
- Apply findings from clinical trials into clinical practice
- Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
- Evaluate the safety and cardiorenal benefits of glucose-lowering agents
- Implement the new guidelines of the HFA of the ESC in clinical practice
More from this programme
State of the Art 1
SGLT2 Inhibitors in Heart Failure: A Practical Approach
Meet The Expert: Implications for Clinical Practice - Breakout 1
Meet The Expert: Implications for Clinical Practice - Breakout 2
Meet The Expert: Implications for Clinical Practice - Breakout 3
State of the Art 2
SGLT2 Inhibitors for Heart Failure: The New Standard of Care
Meet The Expert: Implications for Clinical Practice - Breakout 4
Meet The Expert: Implications for Clinical Practice - Breakout 5
Meet The Expert: Implications for Clinical Practice - Breakout 6
Professor/Honorary Consultant (Institute of Cardiovascular & Medical Sciences)
Professor Mark Petrie worked as an interventional cardiologist before his professorship at University of Glasgow. His interests include revascularization in heart failure, diabetes and cardiovascular disease and cardio-oncology.
Deepak L Bhatt
Executive Director of Interventional Cardiovascular Programs
Dr Deepak Bhatt is Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School.
Dr Bhatt has more than 1,600 publications and has been listed by the Web of Science as a Highly Cited Researcher.
He is Editor of the peer-reviewed Journal of Invasive Cardiology and Editor-in-Chief of the Harvard Heart Letter for patients. He received the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s Hospital in 2017, ACC’s Distinguished Mentor Award in 2018, and AHA’s Distinguished Scientist Award in 2019.